SCHEMBL4338667

SCHEMBL4338667

CN(C)c1ccc2c(c1)OC(N)=C(C#N)C2c1cncc(Br)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.62
KMT2A Q03164 12/20 0.62
MAPT P10636 6/20 0.62
NPSR1 Q6W5P4 4/20 0.62
GAA P10253 4/20 0.62
LMNA P02545 4/20 0.62
HTT P42858 3/20 0.62
TSHR P16473 3/20 0.62
MAPK1 P28482 3/20 0.62
USP2 O75604 2/20 0.62
CASP1 P29466 2/20 0.62
CASP7 P55210 2/20 0.62
TP53 P04637 2/20 0.62
ALOX15 P16050 2/20 0.62
TUBB4A P04350 2/20 0.61
TUBB P07437 2/20 0.61
TUBA3C P0DPH7 2/20 0.61
TUBA1B P68363 2/20 0.61
TUBA4A P68366 2/20 0.61
TUBB4B P68371 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1751883 0.88 MEN1 (0.64) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4333738 0.88 TUBB4A (0.69) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4330162 0.86 MEN1 (0.76) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL30628033 0.85 MEN1 (0.69) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4426413 0.85 MEN1 (0.72) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL28661998 0.85 MEN1 (0.69) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4325072 0.84 MEN1 (0.79) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4333419 0.83 MAPT (0.69) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL4334941 0.83 ALDH1A1 (0.55) MEN1KMT2AMAPTNPSR1GAA
SCHEMBL6422424 0.83 MEN1 (0.54) MEN1KMT2AMAPTNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US claimed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP claimed
US-7507762-B2 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2009-03-24 US disclosed
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US disclosed
US-6906203-B1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-06-14 US disclosed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, CASP5 MEN1 2868/4885KMT2A 3138/4885MAPT 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.